Michael A Ashburn
Pharmacy in Salt Lake City, UT

2005027, Dec 15, 2005

Jun 6, 2005

11/146917

Jie Zhang - Salt Lake City UT, US
Kevin Warner - West Jordan UT, US
Michael Ashburn - Salt Lake City UT, US
Larry Rigby - Salt Lake City UT, US
Suyi Niu - Salt Lake City UT, US

A61K009/70

424448000

The present invention is drawn to adhesive peel-forming formulations for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a peel-forming agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the non-volatile solvent system has a solubility for the drug that is within a window of operable solubility for the drug such that the drug can be delivered at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified peelable layer after at least a portion of the volatile solvent system is evaporated.

2005011, May 26, 2005

Oct 27, 2004

10/975766

Kevin Warner - West Jordan UT, US
Michael Ashburn - Salt Lake City UT, US
Suyi Niu - Salt Lake City UT, US

A61K049/00, A61K009/70

424010100, 424449000

The present invention is drawn to systems and methods for reducing unintended use of an active ingredient, such as residual active ingredients present in spent dermal patches and peels. The system can include a dermal patch including an active ingredient and a destructive agent configured to chemically react with the active ingredient. The destructive agent can be present in a container or an absorber. In one embodiment, the absorber can be used within the container. The container can be configured to receive the dermal patch such that the active ingredient contacts the destructive agent within the container. The absorber can be configured to contact the dermal patch such that the active ingredient contacts the destructive agent of the absorber. Additionally, systems and methods for impeding the unintended use of an active ingredient, such as those present in dermal patches or peels, are also provided. The system includes a dermal patch having a first side configured to deliver an active ingredient to a skin or mucosal surface, wherein the first side also includes a dermal adhesive. The system also includes an adhesive-coated device. The adhesive-coated surface of the device can be configured to adhere to the first side, wherein upon use of the dermal patch followed by contacting the adhesive-coated surface with the first side, residual active ingredient is rendered substantially inaccessible.

2004026, Dec 30, 2004

May 28, 2004

10/856749

Jie Zhang - Salt Lake City UT, US
Kevin Warner - West Jordan UT, US
Michael Ashburn - Salt Lake City UT, US

Zars, Inc.

A61K031/66, A61K009/70, A61N001/30

424/423000, 424/449000, 604/020000

Systems and methods for attenuating a panic attack are provided. Such methods can comprise steps of delivering a drug to a subject such that the drug forms a depot beneath a skin surface, wherein the drug is suitable for attenuating a panic attack if delivered in a pharmaceutically effective amount into systemic circulation of the subject; and applying heat to the skin surface when the subject experiences an onset of the panic attack, thereby causing the pharmaceutically effective amount of the drug to rapidly enter systemic circulation from the depot.